Literature Review: Moving the Druggable Needle
The Use of an mRNA Display Technology and Affinity-Based Selection Is Used to Find Inhibitors to an Enzyme of Interest
To Surge or Not to Surge?
Experts Discuss Inclusion of a Surge Tank in an End-to-End Continuous Biomanufacturing Train
New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Search Results for
Lilly to Use Topas Platform in Immunology Collaboration
August 22, 2017
... which the pharma giant is developing with Incyte-just weeks after the oral Janus kinase 1 and 2 (JAK1/2) inhibitor was approved in Europe under the brand name Olumiant®. ...
Proteins Mapped in Different Mitochondrial Subcompartments for...
August 21, 2017
Proteins Mapped in Different Mitochondrial Subcompartments for First Time A scientific team in Europe says it has mapped the proteins in the different subcompartments of ...
Cancer Genetics to Buy vivoPharm for $12M
August 15, 2017
as a provider of services for oncology discovery, in vivo and in vitro drug development, and early-phase clinical trials testing, and expand its presence in Europe and Australia. ...
Citing Patient Deaths, FDA Panel Faults Safety Data for J&J Arthritis...
August 3, 2017
gained exclusive rights to commercialize sirukumab in North, Central, and South America, while Janssen retained commercialization rights in the rest of the world, including Europe. ...
DNA Fab Keeps Getting More Fab
August 1, 2017
... "At IDT, we have separate cGMP suites that are under ISO 13845 guidance, which enables us to sell products that can be used in FDA-approved kits and are CE Mark-approved in Europe,...
Chiesi Ends Collaboration with uniQure on Hemophilia B Gene Therapy...
August 1, 2017
license a gene therapy for hemophilia B and has returned its development and commercialization rights to the gene therapy candidate in Europe and other areas, uniQure acknowledged. ...
Cellectis Granted T Cell CRISPR Patent in Europe
July 25, 2017
Cellectis Granted T Cell CRISPR Patent in Europe Jonathan Wosen Source: Molekuul/Getty ... Meanwhile, French biotech Cellectis is staking a claim to the technology in Europe. ...
Merck, Samsung Bioepis Launch Remicade Biosimilar in U.S.
July 24, 2017
the U.S., including Europe, while partner Janssen Biotech markets the drug stateside. ... the loss of exclusivity in the U.S. and Europe and launch of competing biosimilars. ...
Mitsubishi Tanabe to Buy Parkinson's Disease Drugs Firm NeuroDerm...
July 24, 2017
Lead LD/CD candidate ND0612 is undergoing Phase III trials in the U.S. and Europe and is projected to launch in 2019. Two subcutaneously administered ND0612 products are in ...
Merck Wins Tentative FDA Approval for Lusduna
July 20, 2017
Lantus lost patent exclusivity in the U.S. and Europe in 2015. Since then, Sanofi has reported sales declines for the drug. Lantus finished the first quarter having generated ...